Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 7/20/2018 |
| Start Date: | October 2007 |
| End Date: | July 2011 |
Vitamin D and Prostate Cancer
This clinical trial is aimed at measuring the effect of vitamin D3 supplementation on serum
prostate-specific antigen (PSA) levels in patients diagnosed with early stage, low-grade,
low-risk prostate cancer (Gleason score less than/equal to 6; PSA less than/equal to 10;
clinical stage T1C or T2a), who elect to have their disease monitored through active
surveillance for at least one year.
prostate-specific antigen (PSA) levels in patients diagnosed with early stage, low-grade,
low-risk prostate cancer (Gleason score less than/equal to 6; PSA less than/equal to 10;
clinical stage T1C or T2a), who elect to have their disease monitored through active
surveillance for at least one year.
Inclusion Criteria:
- lowgrade prostate cancer
- serum PSA less than/equal to 10 ng/ml
- Gleason score less than/equal to 6
- referred from their treating physician with treatment plan of active surveillance for
one year
- serum creatinine less than/equal to 2.0 mg/dL
- serum phosphate (measured as phosphorus)greater than 2.3 and less than 4.8 mg/dL
- serum calcium greater than 8.5 and less than 10.5 mg/dL
Exclusion Criteria:
- concurrent malignancy, except non-melanoma skin cancer
- history of sarcoidosis
- history of high dose (greater than 1,000 IU daily) vitamin D3 supplementation
- history of hypercalcemia
- treatment with lithium medication
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
